[Current Situation and Issues in Transitional Medicine: A Pediatric Neurology Viewpoint].

The transition from pediatric neurology to adult neurology is not easy for patients with childhood-onset neurological or muscular diseases. The reasons can be broadly categorized into patient-related and transition system issues. To resolve these issues, the following are important: 1)promoting awareness of the necessity of future transition among patients and their families during childhood, 2)establishing a transition support team to coordinate the transitions and collect information about medical institutions for adults that can accept patients who need transition, and above all, 3)facilitating close communication and information sharing between the concerned adult and pediatric neurologists.

Declining use of neurological eponyms in cases where a non-eponymous alternative exists.

Eponyms are common in neurology, but their use is controversial. Recent studies have demonstrated increasing eponym use over time in the scientific literature, but it is unclear whether this is a result of authors choosing to use eponyms more frequently, or is merely a product of increasing rates of scientific publication. Our goal was to explore trends in decision-making pertaining to eponym usage. We identified cases where an eponym and a corresponding non-eponymous term existed, and assessed temporal trends in the relative usage of these terms using Google's n-gram viewer for each decade from 1900-2019. Relative to corresponding non-eponymous terms, the use of eponyms increased across the 20th century, peaking in the decade from 1980 to 1989, before sharply declining after the turn of the 21st century. This indicates that when faced with a choice between using an eponym and non-eponymous term, contemporary authors increasingly chose the non-eponymous term. This recent trend may reflect increased awareness of the limitations of eponyms, greater attention to the personal and political lives of namesakes, and a cultural shift toward viewing scientific advances as the result of collective and collaborative efforts rather than the solitary achievements of eminent individuals.

Medical Devices; Neurological Devices; Classification of Cranial Motion Measurement Device. Final order.

The Food and Drug Administration (FDA or Agency) is classifying the cranial motion measurement device into class II (special controls). The special controls that will apply to the device are identified in this order and will be part of the codified language for the cranial motion measurement device's classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Medical Devices; Neurological Devices, Classification of the Vibratory Counter-Stimulation Device. Final order.

The Food and Drug Administration (FDA) is classifying the vibratory counter-stimulation device into class II (special controls). The special controls that will apply to the device are identified in this order and will be part of the codified language for the vibratory counter-stimulation device's classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Medical Devices; Neurological Devices; Classification of the Computerized Cognitive Assessment Aid for Concussion. Final order.

The Food and Drug Administration (FDA) is classifying the Computerized Cognitive Assessment Aid for Concussion into class II (special controls). The special controls that will apply to the device are identified in this order and will be part of the codified language for the computerized cognitive assessment aid for concussion's classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Medical Devices; Neurological Devices; Classification of the Thermal System for Insomnia. Final order.

The Food and Drug Administration (FDA) is classifying the thermal system for insomnia into class II (special controls). The special controls that will apply to the device are identified in this order and will be part of the codified language for the thermal system for insomnia's classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Frenkel: ¿un precursor de la neurorrehabilitación? / Frenkel: one of the forerunners of neurorehabilitation?

El término ‘neurorrehabilitación’ es entendido como el proceso destinado a reducir la deficiencia, la limitación de la actividad y la restricción de la participación que padecen las personas como consecuencia de una enfermedad neurológica, y en el que los profesionales involucrados en dicho ámbito tendrán como objetivo la reducción del grado de afectación funcional del paciente. Debido al desconocimiento que existió en relación con la capacidad plástica que presenta el sistema nervioso humano, los orígenes científicos de la rehabilitación neurológica son relativamente recientes, y se sitúan alrededor de la Segunda Guerra Mundial. Sin embargo, existen indicios de que el neurólogo Heinrich Sebastian Frenkel (1860-1931) pudo establecer las bases de la neurorrehabilitación antes de esa época. En relación con los trabajos realizados y publicados por Frenkel, existen referentes históricos que apoyarían la hipótesis de que, considerando sus metodologías de tratamiento empleadas y documentadas, lo que denominó Übungstherapie (gimnasia neurológica) podría considerarse la base de la neurorrehabilitación moderna. Estos conocimientos pudieron haberse tenido en cuenta por multitud de autores que introdujeron dichas experiencias y aprendizajes en los diversos métodos terapéuticos que surgieron con posterioridad, incluso los más novedosos y tecnológicos, si bien las raíces de la neurorrehabilitación aplicada podrían encontrarse a finales del siglo XIX (AU)

Neurorehabilitation is understood as the process intended to reduce the deficiency, limitation of activity and restriction of participation experienced by people as a result of a neurological diseases, and where the professionals involved in this field will aim to reduce the functional involvement degree of the patient. Due to the ignorance existed about the plastic capacity in the nervous system in humans, the scientific origins of neurological rehabilitation is relatively recent, which are located around the Second World War. However, there are signs that the neurologist Heinrich Sebastian Frenkel (1860-1931) was able to establish the basis of neurorehabilitation before that time. There are historical concerning regarding the work conducted and published by Frenkel that would support the hypothesis, based on the characteristics of their treatment employed and documented methodologies, that what he called ‘Übungstherapie’ (neurological gymnastic), it could be considered as the basis of what we consider today as modern neurorehabilitation. This knowledge could have been used by many authors who introduced those experiences and lessons learned to the multiple therapeutic methods that emerged after, even the most innovative and technological, while the roots of neurorehabilitation could be found at the end of the 19th century (AU)

Neuralgia amiotrófica en relación con infección por el virus de la hepatitis E / Neuralgic amyotrophy associated to hepatitis E virus infection

No disponible

Medical Devices; Neurological Devices; Classification of the Computerized Cognitive Assessment Aid. Final order.

The Food and Drug Administration (FDA) is classifying the computerized cognitive assessment aid into class II (special controls). The special controls that will apply to the device are identified in this order, and will be part of the codified language for the computerized cognitive assessment aid's classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

Microdeleción 12p12 que incluye el gen SOX5: un nuevo síndrome con alteración del neurodesarrollo / Microdeletion 12p12 involving SOX5 gene: a new syndrome with developmental delay

Introducción. El gen SOX5 codifica un factor de transcripción implicado en la regulación de la condrogenia y el desarrollo del sistema nervioso. Caso clínico. Niña de 10 años con discapacidad intelectual, alteración conductual y malformaciones menores de este nuevo síndrome con alteración en el neurodesarrollo, con una deleción 12p12 que incluye el gen SOX5. Conclusiones. Se revisan los casos publicados tanto de deleciones intragénicas de SOX5 como de deleciones más grandes que incluyen este gen, y se analizan las correlaciones enotipo-fenotipo y los genes implicados en esta paciente (AU)

Introduction. The SOX5 gene encodes a transcription factor involved in the regulation of chondrogenesis and the development of the nervous system. Case report. We report a 10 years-old girl with developmental delay, behavior problems and dysmorphic features of this new syndrome with developmental delay. She had a 12p12 deletion involving SOX5. Conclusions. We review the reported cases, intragenic SOX5 deletions and larger 12p12 deletions encompassing SOX5. We analyze the genotype-phenotype associations and the genes involved in our patient (AU)

¿Colores, sabores, números?: la sinestesia en una muestra española / Colors, tastes, numbers?: synesthesia in a Spanish sample

Introducción. La sinestesia es un fenómeno neurológico caracterizado por la activación simultánea de dos sistemas (o atributos) sensoriales, uno de los cuales no ha sido estimulado directamente. Dicha activación se produce de una forma involuntaria, automática y consistente a lo largo del tiempo. Objetivo. Estimar la frecuencia relativa de las diferentes modalidades de sinestesia en una muestra española. Sujetos y métodos. Estudio realizado en contextos educativos (55,04%), laborales (20,54%) y digitales (24,4%) mediante el cuestionario de sinestesia de la Fundación Artecittá. Resultados. El análisis de las respuestas de 803 participantes sugiere que un 13,95% de la muestra estudiada experimenta alguna sinestesia. El análisis de la frecuencia relativa de las diferentes modalidades muestra que la más frecuente es la que relaciona conceptos temporales con configuraciones espaciales (44,6%). Un 33,9% percibe colores cuando escucha sonidos o música, un 25,9% asocia colores a los conceptos temporales, un 20,5% asigna género o personalidad a las letras y números, un 10,7% experimenta la modalidad grafema-color, y un 5,4% siente un sabor específico en su boca al escuchar palabras. Conclusiones. Los datos sugieren que la presencia de sinestesia en la muestra española estudiada es elevada y que lainvestigación sobre el fenómeno y sus diferentes modalidades ha de ser abordada basándose en el conocimiento actual sobre su variabilidad fenomenológica y sus bases genéticas y neurofisiológicas. Asimismo, los resultados obtenidos son útiles para ajustar los ítems del cuestionario y aumentar su capacidad discriminativa (AU)

Introduction. Synesthesia is a neural phenomenon in which stimulation in one sensory or cognitive stream leads to associated experiences in a second, unstimulated stream. These activations occur involuntarily, automatically and consistently over time. Aim. To estimate the relative frequency of the different modalities of the phenomenon in a Spanish sample. Subjects and methods. Study performed in educational (55.04%), labor (20.54%) and digital contexts (24.4%) using the Synesthesia Questionnaire created by Artecittá Foundation. Results. The analysis of the responses given by 803 participants suggests that 13.95% of the sample experience any synesthesia. The analysis of the relative frequencies shows that the most frequent modality is spatial sequence synesthesia (44.6%). 33.9% see colors when listening to sounds and/or music, 25.9% associate colors to temporal concepts, 20.5% assign gender and personality to letters and numbers, 10.7% experience grapheme-color synesthesia and 5.4% feel a specific flavor when hearing words. Conclusions. These data suggest that the presence of synesthesia in the Spanish sample under study is high, and that the investigation of the phenomenon and its different modalities needs to be approached on the basis of the current knowledge about its phenomenological variability and its genetic and neurophysiologic characteristics. Likewise, the results are useful to adjust the questionnaire items and increase their discriminative power (AU)

Medical devices; neurological devices; classification of the neuropsychiatric interpretive electroencephalograph assessment aid. Final order.

The Food and Drug Administration (FDA) is classifying the neuropsychiatric interpretive electroencephalograph (EEG) assessment aid into class II (special controls). The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.